北京科兴成为流感疫苗供应国际行动组（IVS）成员

    2007年5月14日，国际制药企业协会联合会（IFPMA）在日内瓦宣布，流感疫苗供应国际行动组（IVS）接纳北京科兴生物制品有限公司为新成员。成员的标准是开展创新型流感疫苗的研究、遵守并保护知识产权、遵守GMP。
    IFPMA主席Bale博士指出：“流感疫苗供应国际行动组热烈欢迎研发型流感疫苗企业的加入。北京科兴生物制品有限公司是第一个加入IFMPA的中国公司，这表明了中国正在成为医药卫生研发领域的一支力量……流感疫苗供应国际行动组的新技术将有助于在发生流感大流行时保护更多的人。”
    国际制药商协会联盟（IFMPA）是一个非盈利、非政府组织，代表全球26家研发型的医药、生物技术、疫苗企业和60个国家工业协会。IFPMA致力于全球预防性和治疗性药物与疫苗的创新政策、国际合作。
    流感疫苗供应国际行动组（IVS）于2002年成立，成员来自全球研发型流感疫苗制造厂家，这些厂家开展流感和大流感方面的安全、高效、高质量疫苗的R&D。IVS强调并促进流感和大流感疫苗的交流、决策、法规、科学、技术等诸方面的工作。IVS成员利用其在疫苗R&D、物流、生产、安全与法规等方面的专业知识，协助政府和政府间组织制定大流感应对计划和决策。

附：英文原文
IFPMA Influenza Vaccine Supply International Task Force Welcomes Sinovac and PowderMed as its Latest Members
IFPMA IVS
 
Geneva, 5/14/2007 - Geneva, 14 May 2007 – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announces that the IFPMA Influenza Vaccine Supply (IVS) international task force has admitted Sinovac Biotech Ltd. and PowderMed Ltd. as members. Both companies satisfy IVS membership criteria; conducting innovative influenza vaccine research, practicing robust intellectual property protection and complying with GMP (Good Manufacturing Practice).
Dr. Harvey Bale, Director General of the IFPMA, said: “The IFPMA IVS seeks to be as broadly representative as possible and is keen to welcome all research-based influenza vaccine manufacturers. Sinovac, the first Chinese company to join the IFPMA family, is confirmation of China’s move to become a force in research-based health care. PowderMed is opening up a new field of innovation, working on DNA-based vaccines which promise to be easier to produce, deliver and administer than conventional vaccines. This and other new technologies being worked on by other IVS members could help the industry to protect more people in the event of an influenza pandemic.”
Sinovac focuses on the research, development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for new health threats such as SARS and avian influenza. Its headquarters and R&D facility are located in the Beijing University Biological Industry Park, and it is the only Chinese vaccine company listed on an American Stock Exchange. Sinovac's partners include the Chinese National Institutes for Animal Science, Infectious Disease Control, and Viral Disease Control and Prevention.
PowderMed is a UK-based company focused on the development and manufacture of DNA-based vaccines for viral diseases and cancer. DNA vaccines offer the potential of faster manufacturing and should not need a refrigerated supply chain. PowderMed vaccines are delivered using a virtually painless needle-free delivery system that requires minimal medical training and allows self-administration.

【原文网址】http://www.ifpma.org/News/NewsReleaseDetail.aspx?nID=7301